Research programme: obesity therapies - BioconAlternative Names: NLC-002
Latest Information Update: 10 Apr 2007
At a glance
- Originator Biocon
- Mechanism of Action Cholecystokinin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 27 Feb 2004 NLC 002 is available for partnering for obesity worldwide (2nd Annual BioPartnering North America Conference (BPN-2004) (http://www.nobexcorp.com)
- 24 Sep 2002 Lead compound of the programme has been identified as NLC 002
- 19 Mar 2002 Preclinical trials in Obesity in USA (PO)